Chugai Pharmaceutical Co., Ltd. Unsponsored ADR (OTCMKTS:CHGCY) Short Interest Up 144.0% in September

Key Points

• Chugai Pharmaceutical Co., Ltd. saw a significant rise in short interest of 144.0% in September, increasing from 15,900 shares to 38,800 shares.
• As of the latest trading data, Chugai Pharmaceutical's stock price reached $23.69 with a market cap of $77.96 billion.
• The company reported an earnings per share (EPS) of $0.20 for the past quarter and anticipates a forecasted EPS of 0.74 for the current fiscal year.

Chugai Pharmaceutical Co., Ltd. Unsponsored ADR (OTCMKTS:CHGCY - Get Free Report) was the target of a significant increase in short interest during the month of September. As of September 15th, there was short interest totaling 38,800 shares, an increase of 144.0% from the August 31st total of 15,900 shares. Based on an average trading volume of 230,500 shares, the days-to-cover ratio is currently 0.2 days. Based on an average trading volume of 230,500 shares, the days-to-cover ratio is currently 0.2 days.

Chugai Pharmaceutical Stock Performance

CHGCY traded up $0.53 during trading on Friday, reaching $23.69. The stock had a trading volume of 18,542 shares, compared to its average volume of 202,701. The stock has a market cap of $77.96 billion, a PE ratio of 29.99 and a beta of 0.64. Chugai Pharmaceutical has a one year low of $19.50 and a one year high of $31.26. The business has a 50-day moving average of $22.57 and a 200-day moving average of $24.36.

Chugai Pharmaceutical (OTCMKTS:CHGCY - Get Free Report) last released its earnings results on Thursday, July 24th. The company reported $0.20 EPS for the quarter. Chugai Pharmaceutical had a return on equity of 20.80% and a net margin of 33.08%.The business had revenue of $2.01 billion for the quarter. Equities research analysts forecast that Chugai Pharmaceutical will post 0.74 EPS for the current fiscal year.

Chugai Pharmaceutical Company Profile

Chugai Pharmaceutical Co, Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally. The company's products for oncology primarily include Avastin, FoundationOne, Polivy, Rozlytrek, Tecentriq, Perjeta, Alecensa, Herceptin, Kadcyla, Rituxan, and Gazyva; Edirol, an Osteoporosis agent; Mircera, an erythropoiesis agent; Oxarol, an agent for secondary hyperparathyroidism; and other diseases comprise Hemlibra, CellCept, Bonviva, Tamiflu, Evrysdi, Ronapreve, Vabysmo, and Enspryng.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.